Compare CSX Corporation (CSX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Recursion Pharmaceuticals Inc — how do they compare? CSX Corporation trades at $47.37 (market cap $86.70B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: CSX Corporation is far larger — about 37.5× Recursion Pharmaceuticals Inc's market cap, and CSX Corporation pays a 1.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| CSX | RXRX | |
|---|---|---|
Market Cap | $86.70B | $2.31B |
Volume | 6,811,485 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $53.21 | $6.79 |
52-Week Low | $33.68 | $2.84 |
Typical Hold Time | 55 Days | 22 Days |
Enterprise Value | $104.66B | $1.83B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, down 0.34% today, with a bearish technical signal from moving averages. Recent earnings show mixed quarterly results, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though net income margin remains strong at 22.21%. Analyst consensus is bullish with a $51.00 price target, supported by institutional buying and positive news on dividend sustainability.
The outlook for CSX hinges on reversing revenue declines and executing on projected 2026 growth. Risks include competitive pressures and economic sensitivity, but strong profitability and analyst support offer upside. Investors should weigh valuation premiums against operational resilience in the freight sector.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
